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Non-small Cell Lung Cancer
Thomas E. Stinchcombe, MD,* Amy H. Peterman, PhD,† Carrie B. Lee, MD, MPH,*
Dominic T. Moore, MPH,‡ Jennifer L. Beaumont, MS,§ Daniel S. Bradford, MD, Kamal Bakri, MD,¶
Mark Taylor, MD,# Jeffrey M. Crane, MD,** Garry Schwartz, MD,†† Thomas A. Hensing, MD,‡‡
Edwin McElroy, Jr., MD,§§ Harvey B. Niell, MD, Harry D. Harper, MD,¶¶ Sridhar Pal, MD,##
and Mark A. Socinski, MD*
Introduction: Single-agent gemcitabine is a standard of care for
elderly patients with advanced non-small cell lung cancer, but novel
therapies are needed for this patient population.
Methods: We performed a noncomparative randomized phase II
trial of gemcitabine, erlotinib, or the combination in elderly patients
(age 70 years) with stage IIIB or IV non-small cell lung cancer.
Patients were randomized to arms: A (gemcitabine 1200 mg/m2 on
days 1 and 8 every 21 days), B (erlotinib 150 mg daily), or C
(gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days and
erlotinib 100 mg daily). Arms B and C were considered investiga-
tional; the primary objective was 6-month progression-free survival.
Results: Between March 2006 and May 2010, 146 eligible patients
received protocol therapy. The majority of the patients (82%) had
stage IV disease, 64% reported adenocarcinoma histology, 90%
reported current or previous tobacco use, and 28% had a perfor-
mance status of 2. The 6-month progression-free survival rate
observed in arms A, B, and C was 22% (95% confidence interval
[CI] 11–35), 24% (95% CI 13–36), and 25% (95% CI 15–38),
respectively; the median overall survival observed was 6.8 months
(95% CI 4.8–8.5), 5.8 months (95% CI 3.0–8.3), and 5.6 months
(95% CI 3.5–8.4), respectively. The rate of grade 3 hematological
and nonhematological toxicity observed was similar in all three
arms. The best overall health-related quality of life response did not
differ between treatment arms.
Conclusions: Erlotinib or erlotinib and gemcitabine do not warrant
further investigation in an unselected elderly patient population.
Key Words: Quality of life, Cumulative illness rating scale for
geriatrics, Targeted therapy, Elderly.
(J Thorac Oncol. 2011;6: 1569–1577)
Lung cancer remains the leading cause of cancer mortalityin the United States and the world, with approximately
85% of cases non-small cell lung cancer (NSCLC).1–3 The
majority of patients with NSCLC have advanced disease at
the time of diagnosis, and the goals of treatment are to extend
survival, improve health-related quality of life (HRQL), and
reduce disease-related symptoms.4,5 Many elderly patients
with advanced NSCLC have significant cardiovascular and
pulmonary comorbidities related to tobacco exposure and
comorbidities associated with advanced age, which impacts
their ability to tolerate the treatment of NSCLC. According to
the Surveillance, Epidemiology, and End Results registry, the
median age at the time of diagnosis of lung cancer in the
United States is 69 years.6 The definition of “elderly” has
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varied among oncology trials, but for trials of advanced
NSCLC, the age 70 years is frequently used.7 The number
of elderly patients with advanced NSCLC is expected to
increase as the size elderly population continues to increase in
the next several decades.8
Elderly specific trials compared with age-unspecified
trials recruit a more elderly population; among elderly pa-
tients in elderly specific trials compared with age-unspecified
trials, a lower rate of grade3 toxicities is observed.9 Several
elderly specific phase III trials in advanced NSCLC had been
performed when this trial was designed. Single-agent vinore-
lbine was compared with best supportive care (n  161), and
patients assigned to the vinorelbine arm experienced longer
survival, improvement in quality of life (Qol) functioning
scales, and fewer lung cancer-related symptoms.10 A subse-
quent phase III trial (n  698) compared single-agent vinore-
lbine or gemcitabine with the combination of gemcitabine
and vinorelbine; the combination was not more effective than
single-agent vinorelbine or gemcitabine.11 The Qol was sim-
ilar in all three treatment arms but a higher rate of toxicity
was observed in the combination arm. A smaller phase III
trial (n 120) compared vinorelbine with the combination of
gemcitabine and vinorelbine; the combination was associated
with superior survival and a delay in symptom and Qol
deterioration.12 When this trial was designed, single-agent
vinorelbine or gemcitabine were considered standard thera-
pies for elderly patients with advanced NSCLC.
A single-arm phase II trial of erlotinib, an epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR TKI),
in elderly patients with advanced NSCLC had revealed prom-
ising survival and a low rate of toxicity.13 A single-arm phase
II trial of docetaxel and gefitinib in elderly patients with
advanced NSCLC revealed acceptable toxicity and promising
efficacy.14 The combination of gemcitabine and erlotinib
compared with single-agent gemcitabine had revealed supe-
rior survival in patients with advanced pancreatic cancer;15 of
the patients enrolled in the gemcitabine and erlotinib arm,
80% received an erlotinib dose of 100 mg daily. Data report-
ing the efficacy and toxicity of gemcitabine and erlotinib in
advanced NSCLC were not available when this trial was
designed and the role of EGFR mutations in the selection of
patients for EGFR TKI therapy was not known when this trial
was designed. We designed a randomized phase II trial to
investigate the activity of erlotinib alone and in combination
with gemcitabine in elderly patients with advanced NSCLC.
PATIENTS AND METHODS
Eligibility Criteria
Patients were required to have a histologic or cytologic
diagnosis of stage IIIB or IV NSCLC (all histologies), aged
70 years, and have an Eastern Cooperative Oncology
Group performance status (PS) of 0 to 2. Patients could not
have received treatment for metastatic NSCLC; patients
could have received prior adjuvant chemotherapy, but time
since prior adjuvant chemotherapy was required to be 1
year. Patients were required to have adequate hematological
function (defined as absolute neutrophil count [ANC]1500/
mm3, platelets count 100,000/mm3, hemoglobin 8.0
g/dl), hepatic function (defined as aspartate aminotransferase
[AST] and alanine aminotransferase [ALT] 2.5  upper
limit of normal [ULN], alkaline phosphatase [AP] 4 
ULN, and total bilirubin ULN), and renal function (defined
as serum creatinine 1.5  ULN). Patients were required to
have evaluable disease by RECIST.16 Patients with asymp-
tomatic treated brain metastases were eligible. Patients with a
history of severe hypersensitivity reactions to gemcitabine,
incompletely healed from previous oncologic or major sur-
gery, unable to participate in the HRQL questionnaires or
provide informed consent were ineligible. This trial was
reviewed and approved by the institutional review board of
all the participating centers, and patients were required to
provide informed consent before any study related tests were
performed. The study was registered with ClinicalTrials.gov
(NCT00283244).
Treatment
Patients assigned to arm A received gemcitabine 1200
mg/m2 intravenously on days 1 and 8 every 21 days until
disease progression, unacceptable toxicity, or a maximum of
four cycles. At the time of disease progression, patients were
offered erlotinib 150 mg orally daily until disease progression
or unacceptable toxicity. Patients assigned to arm B received
erlotinib 150 mg orally daily until disease progression or
unacceptable toxicity, and patients assigned to arm C re-
ceived gemcitabine 1000 mg/m2 intravenously on days 1 and
8 every 21 days in combination erlotinib 100 mg daily. In arm
C, patients received gemcitabine until disease progression,
unacceptable toxicity, or for a maximum of four cycles; after
four cycles of gemcitabine, patients continued single-agent
erlotinib until disease progression or unacceptable toxicity.
Patients in arm C could undergo dose escalation of erlotinib
to 150 mg daily in cycle 2 at the discretion of the treating
physician if no grade2 or higher toxicity typical of erlotinib
was observed during the first cycle. In all three treatment
arms, 21 days was considered one cycle.
For patients who experienced grade 3 rash or diarrhea
related to erlotinib, treatment was interrupted until toxicity
resolved to grade 1 and then resumed erlotinib with a 50
mg dose reduction. For the second episode of grade 3, rash
or diarrhea the erlotinib dose was reduced to 50 mg in arm
B and 25 mg in arm C. Patients discontinued study treat-
ment if they developed grade 4 rash, diarrhea, or possible
interstitial lung disease.
Patients were required to have an ANC 1500/mm3
and a platelet count 100,000/mm3 before the next cycle; if
the ANC or platelets were below the threshold, they were
checked weekly. If ANC and platelets were not within ac-
ceptable limits after more than 2-week delay, the patient
discontinued study treatment. If a patient experienced
febrile neutropenia, an ANC less than 500/mm3 for 5
days, or platelet count less than 50,000/mm3, the gemcit-
abine dose in arm A was reduced from 1200 mg/mm3 to
900 mg/m2: in arm C, the gemcitabine dose was reduced
from 1000 to 800 mg/m2. For day 8 gemcitabine treatment,
patients were required to have an ANC 1000/mm3 and a
platelet count more than 75,000/mm3 to receive the full
dose of gemcitabine; patients with ANC of 500 to 999/
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mm3 or platelet count 50 to 74,000/mm3 received 75% of
the day 1 gemcitabine dose. The day 8 gemcitabine was
omitted for patients with ANC less than 500/mm3 or
platelet count less than 50,000/mm3.
Study Assessments
Patients were required to have a staging computed tomog-
raphy scan of the chest and abdomen (including the liver and
adrenals) within 4 weeks of trial enrollment. Bone scan, positron
emission tomography, and computed tomography or magnetic
resonance imaging of the brain were not required and were
performed if clinically indicated. Patients underwent laboratory
assessment with a complete blood count (CBC), AST, ALT, AP,
and creatinine; assessment of Eastern Cooperative Oncology
Group PS; and physical examination at baseline visit. Patients
were assessed using the Cumulative Illness Rating Scale for
Geriatrics at baseline (Figure 1).17 Patients had tumor specimens
and blood samples collected for a correlative science studies,
which will be reported separately.
Before each treatment cycle; patients underwent a lab-
oratory examination (CBC, AST, ALT, AP, and creatinine),
physical examination, and toxicity assessment using the
Common Toxicity Criteria for Adverse Events version 3.0
(National Cancer Institute, Bethesda, MD). Patients in the
gemcitabine containing arms had a CBC assessed weekly for
hematological toxicity. Response was assessed according to
RECIST after cycles 2 and 4 and then at 6 months from start of
treatment or if clinically indicated; after 6 months, response was
assessed every 2 months.
HRQL and Symptom Assessment
Participants’ HRQL was evaluated using the functional
assessment of cancer therapy for lung cancer (FACT-L),18,19
which consists of the FACT-General and the lung cancer-
specific subscale (LCS). The FACT-General is a measure of
general Qol and contains the subscales of physical well-being,
social/family well-being, emotional well-being, and functional
well-being (FWB). The Trial Outcome Index-Lung (TOI-L)
consists of the physical well-being, FWB, and LCS subscales.
The TOI-L was the primary HRQL indicator analyzed, with the
total FACT-L and LCS used as secondary indicators.
The FACT-L was administered at the screening visit
(within 2 weeks of day 1 of the first treatment cycle) or on
day 1, after each cycle (3 weeks), after completion of treat-
ment, or at the time the patient was withdrawn from the study.
Patients completed the questionnaire in private before the
doctor’s visit or any investigations or discussions with the
patient about his or her disease status or treatment.
Statistical Methods and Study Design
Efficacy Analysis
The objective of this randomized phase II trial was to test
if one or both of the investigational arms (B and C) would be
worthy of further investigation; arm A was used as an “internal
control” arm to ascertain if the progression-free survival (PFS)
rate in this cohort of patients differs substantially from that of the
previous trial of single-agent gemcitabine.11 The randomized
phase II design was not meant to be comparative between the
treatment arms. The primary endpoint was 6-month PFS, and the
6-month PFS observed with single-agent gemcitabine in a pre-
vious phase III trial was 29%.11 If a 6-month PFS of 45% was
observed in arms B and C, then the treatment would be consid-
ered worthy of further investigation. With an  error of 10%, 49
patients per arm (a total of 147) provided an 85% power to reject
the null hypothesis of 6-month PFS of 29%. Patients were
stratified based on gender, smoking status (never [never defined
as 100 cigarettes in a lifetime] or light [10 pack-years and
quit 15 year ago] versus current or former smoker and PS (0
or 1 versus 2) using a constrained block randomization. PFS was
defined as time between enrollment and disease progression or
death, which ever event occurred first, with censoring for pa-
tients alive without progression at last contact. Overall survival
(OS) was defined as time between enrollment and death or last
contact. Estimates of median PFS and OS and 6-month PFS
were calculated using the Kaplan-Meier method.20
Statistical analyses related to efficacy were performed
using both SAS and R statistical software. SAS statistical
software version 9.2 (SAS Institute Inc., Cary, NC) was used.
R is an open source statistical programming language from
the R Development Core Team (2008; R: A language and
environment for statistical computing; R Foundation for Sta-
tistical Computing, Vienna, Austria. ISBN 3-900051-07-0;
http://www.R-project.org).
HRQL Analysis
The completeness of the HRQL data was described by
calculating the number of forms completed by each subject
PATIENT AGE
RATER DATE
  Instructions:  Please refer to the CIRS-G manual.  Write brief descriptions of the medical problem(s) 
that justified the endorsed score on the line following each item.  (Use reverse side for more writing 
space).
RATING STRATEGY 0- No 
problem 
1- Current mild problem or past significant problem 
2- Moderate disability or morbidity/requires “first line” therapy 
3- Severe/constant significant disability/”uncontrollable” chronic problems 
4- Extremely severe/immediate treatment required/end organ failure/severe impairment in function 
SCORE
1 HEART……………………………………………………………………………............... 
2 VASCULAR…………………………………………………………………………..….....
3 HAEMATOPOIETIC…………………………………………………………………......... 
4 RESPIRATORY……………………………………………………..……………………...
5 EYES, EARS, NOSE, THROAT AND LARYNX……………………..…………….......... 
6 UPPER GI………………………………………………..………………………………….
7 LOWER GI……………………………………………..…………………………………...
8 LIVER………………………………………...…………………………………………......
9 RENAL………………………………………..………………………………………….....
10 GENITOURINARY………………………………..…………………………………….....
11 MUSCULOSKELETAL/INTEGUMENT……………..…………………………………... 
12 NEUROLOGICAL……………………………………..…………………………………...
13 ENDOCRINE/METABOLIC AND BREAST………..……………………………………. 
14 PSYCHIATRIC ILLNESS……………………………..…………………………………... 
TOTAL NUMBER OF CATEGORIES ENDORSED…………………………..………… 
TOTAL SCORE…………………………………………………………………………..… 
Severity index:  (total score/total number of categories endorsed)………………………… 
Number of categories at level 3 severity…………………………………………………..... 
Number of categories at level 4 severity…………………………………………………..... 
FIGURE 1. Cumulative Illness Rating Scale for Geriatrics
(CIRS-G).17
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divided by the number of forms expected. A questionnaire
was considered completed if enough questions were an-
swered to obtain a valid total score. Analyses focused on the
assessments at baseline (cycle 1 day 1 if available, otherwise
used pretreatment screening data), cycle 2, cycle 3, cycle 4,
and at end of treatment (EOT). Before conducting the pri-
mary analyses, patterns of missing data across these time
points were summarized. Patients were classified as “com-
pleters” if they completed an EOT assessment and as “non-
completers” otherwise. Baseline TOI, FACT-L, and LCS
scores were compared between completers and noncom-
pleters. A 2 test was also conducted to evaluate whether the
proportion of completers differed between study arms. All
HRQL analyses were performed using SAS version 9.2 (SAS
Institute Inc.).
HRQL treatment response scores were calculated
based on absolute change from baseline to each subsequent
assessment point and were classified as improved, wors-
ened, or no change based on previously reported estimates
of clinically significant change.21 On the TOI-L and
FACT-L, a change of 6 points or more indicated change.
For the LCS, a change of 2 or more points indicated
change. The best overall HRQL response to treatment was
then determined as follows. Two visits with a response of
“improved” without an interim visit response of worsened
was required to be classified as an improvement. A best
response of “no change” was assigned to subjects who did
not qualify for “improved” but who had two visit responses
of “improved” or “no change” with no interim visit where
HRQL “worsened.” A best overall response of “worsened”
was assigned for those subjects who had two consecutive
visit responses of “worsened.” Subjects who did not meet
any of these criteria were assigned an overall treatment
response of “other.”
Finally, we calculated the percentage of subjects in
each treatment arm who fell into each overall treatment
response category. A score improvement rate was calculated
as the percentage of patients with best overall score response
of “improved.” A score control rate was calculated as the
percentage of patients with a best overall score response of
either “improved” or “no change.” A score worsened rate was
calculated as the percentage of patients with a best overall
score response of “worsened.”
No expected HRQL increase was specified a priori.
Instead, 2 statistics were used to compare visit responses
between treatment arms at each assessment and overall
rate of improvement, worsening, or no change. We also
used a mixed effects model for repeated measures to
evaluate the TOI-L, FACT-L Total, and LCS scores lon-
gitudinally. Mixed effects models describe the rate of
change in HRQL scores over time for each treatment arm
(fixed effect), taking into account the between-patient
variability by incorporating each patient’s individual start-
ing point and individual rate of change (random effect)
into the model. Mixed effects models use all available data
and do not discard subjects from the overall analysis when
individual assessments are missing.
RESULTS
Patients
Between March 2006 and May 2010, 160 patients were
enrolled on the trial (Figure 2); 13 patients did not initiate
study treatment because of the following reasons: withdrew
informed consent (n  5), referred to hospice (n  4),
ineligible (n  3), and death before treatment (n  1). One
patient received treatment on trial and was subsequently
found to be ineligible because of an incorrect diagnosis. The
characteristics of the patients enrolled and treated on the trial
are presented in Table 1. The median age in treatment arms
A, B, and C was 74, 76, and 78 years, respectively. The
majority of the patients had stage IV disease (82%), and
adenocarcinoma histology (64%). Of the patients with a
known smoking history, approximately 90% of patients were
current smokers or had a history of smoking, and 28% of
patients had a PS of 2. The median Cumulative Illness Rating
Scale for Geriatrics score in arms A, B, and C was 11.5, 10,
and 11, respectively.
Treatment Administration and Toxicity
The median number of cycles in treatment arms A, B,
and C was 4 (range 1–4), 2 (range 1–39), and 4 (range 1–9),
respectively. The most common reasons for treatment discon-
tinuation were adverse events and disease progression (Figure
2). Of the 44 patients in arm A, 19 received erlotinib at the
time of disease progression; in arms B (n  51) and C (n 
FIGURE 2. Trial schema and patient flow diagram.
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51), 12 and 9 patients, respectively, received further therapy
at the time of disease progression therapy. The rate of grade
3 hematological toxicities observed in arms A, B, and C
are presented in Table 2; the rate of grade 3 neutropenia
was low in all three arms, and no episodes of febrile
neutropenia were observed. The rate of grade 3 treat-
ment-related nonhematological toxicities occurring in
5% of patients is presented in Table 3. The rate of grade
3 nonhematological toxicities was 10% in all 3 treat-
ment arms. Two grade 5 toxicities (pneumonitis and renal
failure) were observed in arm C; no grade 5 toxicities were
observed in the other treatment arms. The rate of acne/
acneiform rash (all grades) observed in arms A, B, and C
was 20, 45, and 47%, respectively.
Efficacy Results
The median follow-up for survivors is 12.3 months
(range 3.5–39 months). Of the 146 patients treated in the trial,
140 have experienced disease progression or death. The
6-month PFS observed in arms A, B, and C was 22% (95%
confidence interval [CI] 11–35), 24% (95% CI 13–36), and
25% (95% CI 15–38), respectively; the median PFS was 3.7
(95% CI 2.3–4.7), 2.8 (95% CI 1.4–3.4), and 4.1 (95% CI
2.4–5.0) months, respectively (Table 4 and Figure 3). Of the
146 patients treated in the trial, 130 have died. The median
OS observed in arms A, B, and C was 6.8 (95% CI 4.8–8.5),
5.8 (95% CI 3.0–8.3), and 5.6 (95% CI 3.5–8.4) months,
respectively (Table 4 and Figure 4). The overall response rate
observed in arms A, B, and C was 7, 0, and 21%, respec-
tively. Of the 45 patients who received treatment in arm A, 19
patients received second-line erlotinib, and 18 patients have
experienced disease progression or death. The response rate
and median PFS observed with second-line erlotinib was 11%
(95% CI 1–33; 2 patients) and 1.6 months (95% CI 0.9–3.7
months), respectively. Second-line therapy in treatment arms
B and C was at the discretion of the investigator, and data are
not available on the agent used or the efficacy observed.
HRQL Analysis
Baseline TOI, FACT-L, and LCS scores did not differ
between completers and noncompleters (p  0.58). A 2 test
was also conducted to evaluate whether the proportion of
completers differed between study arms: it did not (p 
TABLE 1. Patient Characteristics
Characteristic Gemcitabine Erlotinib
Gemcitabine/
Erlotinib
n 44 51 51
Median age, yr (range) 74 (70–86) 76 (69–86) 78 (70–90)
Stage, n (%)
IIIB 11 (25) 5 (10) 10 (20)
IV 33 (75) 46 (90) 41 (80)
Gender, n (%)
Male 22 (50) 24 (47) 27 (53)
Female 22 (50) 27 (53) 24 (47)
Performance status, n (%)
0 10 (23) 7 (14) 6 (12)
1 21 (48) 29 (57) 29 (57)
2 13 (29) 14 (27) 14 (27)
Missing 0 (0) 1 (2) 2 (4)
Smoking history, n (%)
Never or light 4 (9) 6 (12) 5 (10)
Current or former 35 (80) 43 (84) 42 (82)
Missing 5 (11) 2 (4) 4 (8)
Histology, n (%)
Adenocarcinoma 28 (64) 34 (67) 31 (61)
Squamous 7 (16) 5 (10) 8 (16)
Not otherwise specified 8 (18) 12 (23) 12 (24)
Large cell carcinoma 1 (2) 0 (0) 0 (0)
CIRS-G frailty scalea
Median total score (range) 11.5 (0–25) 10 (2–24) 11 (4–24)
Median severity index 0.8 0.7 0.8
No. of categories at level 3 3 0 2
No. of categories at level 4 0 1 0
a Data missing on one patient.
CIRS-G, Cumulative Illness Rating Scale for Geriatrics.
TABLE 2. Grade 3 Hematologic Toxicities
Toxicity
Arm A
(Gemcitabine)
Arm B
(Erlotinib)
Arm C
(Gemcitabine 
Erlotinib)
Anemia 1 (2) 0 (0) 4 (8)
Neutropenia 4 (9) 1 (2) 1 (2)
Thrombocytopenia 3 (7) 1 (2) 2 (4)
Febrile neutropenia 0 (0) 0 (0) 0 (0)
Data are presented as n (%).
TABLE 3. Common (5% in Any Arm) Grade 3
Nonhematologic Toxicities
Toxicity
Arm A
(Gemcitabine)
Arm B
(Erlotinib)
Arm C
(Gemcitabine 
Erlotinib)
Dehydration 0 (0) 3 (6) 2 (4)
Diarrhea 0 (0) 3 (6) 3 (6)
Dyspnea 2 (5) 0 (0) 3 (6)
Fatigue 4 (9) 1 (2) 5 (10)
Rash 1 (2) 2 (4) 3 (6)
Data are presented as n (%).
TABLE 4. Efficacy Results
Gemcitabine Erlotinib
Gemcitabine 
Erlotinib
Overall response
rate, %
7 0 21
Median PFS
(95% CI), mo
3.7 (2.3–4.7) 2.8 (1.4–3.4) 4.1 (2.4–5.0)
6 Month PFS rate
(95% CI), %
22 (11–35) 24 (13–36) 25 (15–38)
Median OS
(95% CI), mo
6.8 (4.8–8.5) 5.8 (3.0–8.3) 5.6 (3.5–8.4)
CI, confidence interval; PFS, progression-free survival; OS, overall survival.
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0.877). Of the completers, 32% were in arm A, 34% were in
arm B, and 34% were in arm C.
Best Response-to-Treatment Analysis
The best overall HRQL response did not differ between
treatment arms on the TOI-L (p 0.76), the LCS (p  0.85),
or the FACT-L total score (p  0.57). These results are
summarized in Table 5. Because a large number of subjects in
each arm were coded as “other” (i.e., they did not meet
criteria for better, no change, or worse), we also examined
whether the response at each assessment time differed across
treatment arms. No significant differences were found in the
percent improved, worsened, or with no change at any of the
individual assessments (p  0.11).
Longitudinal HRQL Analysis
Table 6 contains descriptive statistics for the HRQL
raw scores at each assessment time. Baseline HRQL did not
differ between treatment arms (p  0.48). Both the TOI-L
and the total FACT-L showed a very slight general downward
trend across assessment times that was equivalent between
treatment arms, as indicated by a significant effect for time
(p  0.01 for both) and a nonsignificant time  treatment
interaction (p  0.95) in the mixed model. Although the
overall time treatment interaction effect was not significant
for the LCS either (p  0.62), the post hoc comparisons
indicated that lung cancer symptoms were significantly better
in the combined treatment arm than in the gemcitabine only
FIGURE 3. Progression-free survival by treatment arm.
FIGURE 4. Overall survival by treatment arm.
TABLE 5. Best Response-to-Treatment Analysis
Gemcitabine
(n  44)
Erlotinib
(n  51)
Gemcitabine 
Erlotinib (n  51)
TOI-L
Improved 5 (11.4) 6 (11.8) 7 (13.7)
No change 12 (27.3) 9 (17.6) 9 (17.6)
Worsened 11 (25.0) 12 (23.5) 9 (17.6)
Other 16 (36.4) 24 (47.1) 26 (51.0)
LCS
Improved 7 (15.9) 13 (25.5) 14 (27.4)
No change 7 (15.9) 8 (15.7) 4 (7.8)
Worsened 9 (20.4) 8 (15.7) 6 (11.8)
Other 21 (47.7) 22 (43.1) 27 (52.9)
FACT-L total
Improved 8 (18.2) 9 (17.6) 8 (15.7)
No change 9 (20.4) 6 (11.8) 7 (13.7)
Worsened 8 (18.2) 7 (13.7) 8 (15.7)
Other 19 (43.2) 29 (56.9) 28 (54.9)
Data are presented as n (%).
TOI-L, trial outcome index-lung; LCS, lung cancer symptoms; FACT-L, functional
assessment of cancer therapy for lung cancer.
TABLE 6. Longitudinal Health-Related Quality of Life Scores
Gemcitabine
Only
Erlotinib
Only
Gemcitabine
 Erlotinib
TOI-L
Baseline 52.8 (14.5), 42 50.5 (14.1), 51 54.0 (14.9), 46
Cycle 2 49.6 (10.3), 31 47.8 (15.1), 36 51.9 (16.0), 35
Cycle 3 50.9 (13.3), 27 51.3 (12.8), 22 52.0 (14.0), 25
Cycle 4 52.2 (13.4), 24 50.2 (17.1), 21 56.5 (12.7), 20
End of treatment 46.5 (14.3), 21 44.5 (18.1), 24 48.8 (14.6), 23
FACT-L total
Baseline 93.4 (18.9), 42 91.5 (18.4), 50 95.1 (19.5), 45
Cycle 2 91.3 (14.5), 29 90.0 (17.3), 34 94.0 (21.7), 34
Cycle 3 93.5 (18.9), 26 94.3 (16.4), 21 92.3 (20.3), 24
Cycle 4 95.6 (18.0), 24 91.3 (22.0), 20 99.7 (17.5), 19
End of treatment 84.7 (20.4), 21 83.2 (22.3), 22 90.3 (19.9), 22
LCS
Baseline 16.1 (5.6), 42 15.8 (5.0), 51 17.0 (4.6), 46
Cycle 2 16.1 (3.8), 31 16.2 (5.1), 36 17.4 (5.4), 35
Cycle 3 14.9 (5.2), 27 16.5 (4.5), 23 18.7 (6.0), 25
Cycle 4 16.4 (5.2), 25 15.8 (6.3), 21 19.9 (4.6), 20
End of treatment 14.4 (5.9), 22 15.4 (6.0), 24 17.1 (6.0), 24
Data are presented as mean (SD), n.
TOI-L, trial outcome index-lung; LCS, lung cancer symptoms; FACT-L, functional
assessment of cancer therapy for lung cancer.
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arm at the third (p  0.04) and fourth (p  0.02) cycles and
at the EOT (p  0.04; Figure 5).
DISCUSSION
The 6-month PFS observed in the erlotinib alone arm
did not meet the threshold for further study. When this trial
was designed, the predictive role of EGFR mutation in the
use of first-line EGFR TKI therapy was not known. Phase III
trials compared EGFR TKI’s with platinum-based double
agent chemotherapy support the use of first-line EGFR TKI
therapy in patients whose tumors demonstrated an EGFR
mutations.22–24 Of patients with a known smoking history,
approximately 90% enrolled in our study were consider
current or former smokers, which is a patient population
associated with a lower rate of EGFR mutations. The re-
sponse rate and PFS results of single-agent erlotinib observed
in our trial are similar to first-line gefitinib among patients
with EGFR wild-type tumors in the Iressa Pan-Asia
Study.22,25 The rate of rash in the erlotinib alone and erlotinib
and gemcitabine arms are numerically lower than trials of
maintenance erlotinib and the combination erlotinib and gem-
citabine in pancreatic cancer.15,26 The reasons for this lower
rate of rash are unclear.
The Iressa in NSCLC versus Vinorelbine Investigation
in The Elderly (INVITE) compared gefitinib with vinorelbine
in unselected elderly patients (age 70 years); the primary
endpoint was PFS.27 Patients assigned to gefitinib (n  97)
compared with vinorelbine (n  99) experienced a similar
PFS and OS. The 6-month PFS rate observed in the gefitinib
and vinorelbine arms was 14.9 and 23.6%, respectively; the
overall response rate observed was 3.1 and 5.1%, respec-
tively. Given the randomized phase II design of our trial and
the INVITE trial by Crino et al., definitive conclusions cannot
be determined. However, the data from these two trials
suggest that treatment with first-line EGFR TKI therapy in an
unselected elderly patient population is unlikely to yield
significant improvements in efficacy compared with single-
agent chemotherapy.
HRQL and symptom control are important assessments
when evaluating novel palliative therapies in advanced
NSCLC. The overall HRQL results from the Crino et al.
study did favor the gefitinib arm, with greater percentage of
patients improved on the TOI-L and FACT-L, and the overall
Lung Cancer Symptom (LCS) improvement rates were sim-
ilar with gefitinib and vinorelbine. Single-agent erlotinib did
not result in better HRQL or symptom control than the other
treatment arms in our study. However, the HRQL and symp-
tom improvement rates in our trial seemed to be much lower
than those observed in previous trials of single-agent EGFR
TKI therapy.21,27
The combination of gemcitabine and erlotinib did not
reach the predefined threshold for further study either, based
on 6-month PFS rate. The combined treatment arm seems to
have resulted in a better lung cancer symptom profile by cycle
3, but it was also associated with a numerically higher rate of
grade 3 toxicity. Four other age-unspecified phase III trials
of platinum-based chemotherapy with and without EGFR
TKI therapy did not reveal an improvement in PFS or OS
with the addition of an EGFR TKI in the intent-to-treat
patient population.28–31 The data from these trials and our
trial indicate that it is unlikely that the combination of
chemotherapy and EGFR TKI therapy will result in an
improvement in treatment efficacy in an unselected patient
population.
It is possible that a more morbid patient population was
enrolled in our trial; if so, it may also help to explain the lower
HRQL and symptom response rates in all arms of this trial,
compared with others that have used the same response crite-
ria.18,22 Stable comorbidities that are common in the elderly,
such as congestive heart failure and chronic obstructive pulmo-
nary disease, could make it unlikely that physical and FWB and
pulmonary symptoms would improve to a great extent.
FIGURE 5. Lung Cancer-Specific Subscale Score
by Cycle.
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The 6-month PFS and median OS observed in our trial
with single-agent gemcitabine are similar to the 6-month PFS
and OS observed in the trial by Gridelli et al.11 More recently,
a phase III trial by Quoix et al.32 compared single therapy
(gemcitabine or vinorelbine) with carboplatin and weekly
paclitaxel in patients with advanced NSCLC age 70 to 89
years. A statistically significant superior PFS and OS were
observed among patients in the double agent arm compared
with the single-agent arm. The PFS and OS observed in the
single-agent arm are similar to the PFS and OS observed in
the gemcitabine alone arm in our trial. In the trial by Quoix
et al., among patients receiving single-agent gemcitabine
(n 149), the rate of grade 3 or 4 neutropenia (4.7%), febrile
neutropenia (0%), anemia (2%), and thrombocytopenia
(1.3%) was similar to the frequency of these toxicities in our
trial. In our trial, the only nonhematologic toxicity observed
at a rate of 5% among patients in the gemcitabine arm was
fatigue. Thus, the efficacy and toxicity of gemcitabine are
similar between the two trials, and there is no suggestion that
the single-agent gemcitabine arm “underperformed” in our
trial. The data from the trial by Quoix et al. suggest that for
appropriate elderly patients, double-agent chemotherapy is
the preferred treatment. Although there is often a concern
about the use of chemotherapy doublets in older patients, we
previously demonstrated in a retrospective analysis that pa-
tients older and younger than 70 years had comparable HRQL
changes across 6 months when treated with a regimen of
paclitaxel and carboplatin.33
Elderly specific trials enroll an older patient population
than age unspecified trials.9 Many “fit” elderly patients seen the
participating centers may have been enrolled in trials of plati-
num-based therapy or treated with platinum-based therapy out-
side a clinical trial,5 and the older and more morbid patients may
have been enrolled in our trial. The percentage of patients
receiving further therapy at the time of disease progression in
arms A, B, and C was 43, 24, and 18%, respectively. It is
difficult to determine the reasons for the low rate of second-line
therapy in our trial. The low rate of second-line therapy may
have contributed to the modest OS observed on this trial or may
reflect the inherent prognosis of advanced NSCLC in this patient
population. In the trial by Quoix et al., patients in both arms were
offered erlotinib at the time of disease progression as a part of
the trial design, and the data on the rate of second-line therapy
will be of interest.
In summary, the results of our trial indicate that neither
single-agent erlotinib or in combination with gemcitabine
warrant further investigation in an unselected elderly patient
population.
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